Eli Lilly, Verge Genomics Ink $720M Pact For Amyotrophic Lateral Sclerosis Therapies

  • Verge Genomics has announced a three-year collaboration with Eli Lilly And Co LLY to research and develop novel therapies to treat amyotrophic lateral sclerosis (ALS), a motor neuron disease.
  • Under the terms of the three-year agreement, Verge will receive up to $25 million in upfront equity investment and potential near-term payments, with an additional milestone value of $694 million and potential downstream royalties.
  • Verge will apply its all-in-human platform to discover and validate new targets for ALS. The all-in-human platform is based on a proprietary collection of patient brain transcriptomes across various neurodegenerative diseases.
  • Verge will apply its human-based discovery capabilities to validate targets.
  • Lilly will select up to four targets identified by Verge with plans to advance through clinical development and commercialization.
  • Price Action: LLY shares are down 1.75% at $231.70 in the premarket session on the last check Thursday.
Loading...
Loading...
LLY Logo
LLYEli Lilly and Co
$825.003.89%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
79.83
Growth
81.79
Quality
92.12
Value
3.07
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...